acute coronary syndrome
Conditions
Interventions
Standard lipid lowering therapy with statins. LDL level less than 100mg/dl
Intensive lipid lowering theraphy with both statin and EPA
Intensive lipid lowering theraphy with both statin and EPA+DHA
Sponsors
Department of Cardiovascular Medicine Nara Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients meeting all of the following criteria will be included. 1) ACS patients who have received successful OCT-guided PCI 2) Patients who tolerate statin 3) written concent for participation
Exclusion criteria
Exclusion criteria: Patients meeting all of the following criteria will be excluded. 1) patients who had been taking EPA or EPA+DHA before enrollment 2) bleeding tendency 3) hypersensitivity for EPA or EPA+DHA 4) congestive heart failure 5) refractory unstable angina 6) participating other clinical trials 7) pregnant, lactating, and possibly pregnant women and those planning to become pregnant 8) judged as ineligible by clinical investigators
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in OCT parameter at 8-month follow-up 1) thickness of fibrous cap at non-culprit lipid rich plaque 2) condition of neointimal coverage over implanted stent | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in following paremter at 8-month follow-up 1) lipid core size (OCT) 2) serum plasma profile 3) changes in inflammatory parameters 4) relation between lipid core size and serum lipid profile Changes in following paremter at 12-month follow-up 5) serum lipid profile 6) development of adverse cardiovascular events | — |
Countries
Japan
Contacts
Public ContactMakoto Watanabe
Nara Medical University Department of Cardiovascular Medicine
Outcome results
None listed